Eocene and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of Aramchol
Eocene said its subsidiary Galmed Research & Development and Barcode Nanotech have developed a proprietary Aramchol formulation using FDA-approved lipids. The lipid nanoparticles are designed to direct Aramchol to the tumor microenvironment in liver and GI tumors and selectively inhibit fibrosis-driving cells.
Why it matters — EOCN watchers may care because the formulation is intended to support liver and GI cancer therapies by targeting fibrosis-driving cells, with the stated goal of improving treatment efficacy while minimizing toxicity.